IRWDHIGH SIGNALFINANCIAL10-K

IRWD shows explosive revenue growth of 244% but with deteriorating profitability and a massive 524% increase in current liabilities that creates significant liquidity concerns.

The dramatic surge in current liabilities from $38.8M to $242.2M represents a potential cash flow crisis that could threaten operations despite strong revenue performance. While the company increased cash reserves and conducted substantial share buybacks, the net income decline of 40% alongside 185% higher interest expense suggests unsustainable financial leverage and operational inefficiencies that may require immediate management attention.

Comparing 2026-02-26 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

IRWD experienced explosive top-line growth with revenue surging 244% to $298.3M, accompanied by a significant cash position increase to $215.5M and aggressive share buybacks of $126.4M. However, the financial picture is concerning as net income dropped 40% despite the revenue boom, current liabilities exploded 524% creating potential liquidity stress, and interest expense nearly tripled to $21.6M indicating substantial debt burden increases. The combination of deteriorating profitability margins, massive liability growth, and high leverage suggests the company may be funding unsustainable growth that could pressure future cash flows.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
+523.5%
$38.8M→$242.2M

Current liabilities surged 523.5% — significant near-term obligations; verify ability to meet short-term debt.

Share Buybacks
Cash Flow
+423.8%
$24.1M→$126.4M

Share repurchases increased 423.8% — management returning capital, signals confidence in intrinsic value.

Revenue
P&L
+243.5%
$86.8M→$298.3M

Strong top-line growth of 243.5% — accelerating demand or successful expansion into new markets.

Interest Expense
P&L
+184.7%
$7.6M→$21.6M

Interest expense surged 184.7% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
+143.3%
$88.6M→$215.5M

Cash position surged 143.3% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
-76.1%
$142K→$34K

Capex reduced 76.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+50.3%
$182.4M→$274.2M

Current assets grew 50.3% — improving short-term liquidity or inventory/receivables build.

SG&A Expense
P&L
-43%
$144.3M→$82.3M

SG&A reduced 43% — improved cost efficiency or headcount reduction improving operating margins.

Accounts Receivable
Balance Sheet
-42.9%
$81.9M→$46.7M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Net Income
P&L
-40.1%
$40.1M→$24.0M

Net income declined 40.1% — review whether driven by operations, interest costs, or non-recurring items.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-31
ADDED
Delays in the completion of clinical testing of any of our products or product candidates could result in increased costs and could delay or limit our ability to generate revenues.
Pending, threatened or future legal actions may lead to costs, reputational harm, or adverse outcomes that could materially affect our business.
FDA, in a class of GI medicines called guanylate cyclase type C agonists, or GC-C agonists, and is indicated for the treatment, in the U.S., of irritable bowel syndrome with constipation, or IBS-C, in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation, or CIC, in adults, and functional constipation, or FC, in pediatric patients ages 6-17 years-old.
LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China.
Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
+7 more — sign up free →
REMOVED
Our failure to successfully develop and commercialize additional product candidates or approved products would impair our ability to grow and/or adversely affect our business.
If we are unable to execute on our strategy to in-license or acquire externally developed products or product candidates, or engage in other transactions with value creation potential, our business and prospects would be materially adversely affected.
We have identified material weaknesses in our internal control over financial reporting.
If we are not able to remediate these material weaknesses, it could have an adverse effect on our business and financial results, and our ability to meet our reporting obligations could be negatively affected.
FDA, in a class of GI medicines called guanylate cyclase type C agonists, or GC-C agonists, and is indicated for adult men and women suffering from irritable bowel syndrome with constipation, or IBS-C, or chronic idiopathic constipation, or CIC, and for pediatric patients ages 6-17 years-old suffering from functional constipation, or FC.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →